Using Patient-Reported Outcome Measures (PROMs) to promote quality of care and safety in the management of patients with Advanced Chronic Kidney disease (PRO-trACK project): A mixed-methods project protocol

BMJ Open

Volumn 7, Issue 6, 2017, Pages

  Aiyegbusi, Olalekan Lee ^a   Kyte, Derek ^a   Cockwell, Paul ^a,b   Marshall, Tom ^a   Dutton, Mary ^b   Slade, Anita ^a   Marklew, Neil ^a   Price, Gary ^a   Verdi, Rav ^a   Waters, Judi ^a   Sharpe, Keeley ^a   Calvert, Melanie ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

nephrology; qualitative research; statistics research methods; usability testing

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONSTRUCT VALIDITY; CONVERGENT VALIDITY; HEALTH CARE QUALITY; HOSPITAL MANAGEMENT; HOSPITAL PERSONNEL; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; PATIENT SAFETY; PATIENT-REPORTED OUTCOME; PSYCHOMETRY; QUALITATIVE RESEARCH; RASCH ANALYSIS; RESEARCH ETHICS; CLASSIFICATION; FEASIBILITY STUDY; METHODOLOGY; PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME;

FEASIBILITY STUDIES; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT REPORTED OUTCOME MEASURES; QUALITATIVE RESEARCH; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN;

EID: 85021702871     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-016687     Document Type: Article

References (92)

1. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379:165-80.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
3. Meyer T, Hostetter TT. Medical progress: uremia. N Engl J Med 2007;13:1316-25.
4. Almutary H, Bonner A, Douglas C. Symptom burden in chronic kidney disease: a review of recent literature. J Ren Care 2013;39:140-50.
5. Gapstur RL. Symptom burden: a concept analysis and implications for oncology nurses. Oncol Nurs Forum 2007;34:673-80.
6. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and highrisk population cohorts. Kidney Int 2011;80:93-104.
7. Stringer S, Sharma P, Dutton M, et al. The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol 2013;14:95.
8. FDA. Patient-reported outcome measures: use in medicinal product development to support labeling claims. Guidance for industry. 2009. https://www. fda. gov/ downloads/ drugs/ guidances/ ucm193282. pdf (accessed Feb 2017).
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
10. Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 2011;103:1808-10.
11. Bren L. 'The importance of patient-reported outcomes⋯It's all about the patients' FDA Consumer. 2006. https:// permanent. access. gpo. gov/ lps1609/ www. fda. gov/ fdac/ features/ 2006/ 606-patients. html (accessed Feb 2017).
12. Hjollund NH, Larsen LP, Biering K, et al. Use of patient-reported outcome (PRO) measures at group and patient levels: experiences from the Generic Integrated PRO System, WestChronic. Interact J Med Res 2014;3:e5.
13. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient wellbeing: a randomized controlled trial. J Clin Oncol 2004;22:714-24.
14. Gilbody SM, Whitty PM, Grimshaw JM, et al. Improving the detection and management of depression in primary care. Qual Saf Health Care 2003;12:149-55.
15. Bennett AV, Jensen RE, Basch E. Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 2012;62:336-47.
16. McCann L, Maguire R, Miller M, et al. Patients' perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care 2009;18:156-64.
17. Aiyegbusi OL, Kyte D, Cockwell P, et al. Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: a systematic review protocol. BMJ Open 2016;6:e012014.
18. myhealth @ QEHB University Hospitals Birmingham NHS Foundation Trust. 2016 http://www. uhb. nhs. uk/ myhealth-at-QEHB. htm (accessed Feb 2017).
19. EHI 2014 Awards. Digital Health 2014. http://www. ehilive. co. uk/ ehiawards/ past-winners/ 2014-awards/ best-use-of-technology-to-shareinformation-with-patients-and-carers/
20. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011;305:1553-9.
21. Jesky MD, Dutton M, Dasgupta I, et al. Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study. PLoS One 2016;11:e0165675.
22. Usability. gov. https://www. usability. gov/ (accessed Feb 2017).
23. Nielsen J. Usability engineering. Academic Press Inc, 1994:165.
24. van den Haak M, De Jong M, Jan Schellens P. Retrospective vs. concurrent think-aloud protocols: testing the usability of an online library catalogue. Behav Inf Technol 2003;22:339-51.
25. Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 2012;21:651-7.
26. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.
27. Bryman A. Social research methods. Oxford: Oxford University Press, 2001.
28. Fusch Patricia NL. Are we there yet? Data saturation in qualitative research. The Qualitative Report 2015;20.
29. Rasch G. Probabilistic models for some intelligence and attainment tests. Copenhagen: Danish Institute for Educational Research, 1960.
30. Nunnally J. Psychometric theory. New York: McGraw-Hill, 1978.
31. Prieto L, Alonso J, Lamarca R. Classical test theory versus Rasch analysis for quality of life questionnaire reduction. Health Qual Life Outcomes 2003;1:27.
32. Tennant A, Penta M, Tesio L, et al. Assessing and adjusting for cross-cultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model: the PRO-ESOR project. Med Care 2004;42(1 Suppl):I-37.
33. Yorke J, Horton M, Jones PW. A critique of Rasch analysis using the Dyspnoea-12 as an illustrative example. J Adv Nurs 2012;68:191-8.
34. Pallant JF, Tennant A. An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 2007;46:1-18.
35. Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis & Rheumatism 2007;57:1358-62.
36. Wright BD. Solving measurement problems with the Rasch model. J Educ Meas 1977;14:97-116.
37. Smith EV. Detecting and evaluating the impact of multidimensionality using item fit statistics and principal component analysis of residuals. J Appl Meas 2002;3:205-31.
38. Vet HCWde, Adir HJ, Terwee CB, et al. Are factor analytical techniques used appropriately in the validation of health status questionnaires? A systematic review on the quality of factor analysis of the SF-36. Quality of Life Research 2005;14:1203-18. dicussion 19-21, 23-4.
39. Dexter PR, Stump TE, Tierney WM, et al. The psychometric properties of the SF-36 health survey among older adults in a clinical setting. J Clin Geropsychol 1996;2:225-37.
40. Kaiser HF. The application of electronic computers to factor analysis. Educ Psychol Meas 1960;20:141-51.
41. Cattell RB. The Scree test for the number of factors. Multivariate Behav Res 1966;1:245-76.
42. Wolinsky FD, Stump TE. A measurement model of the Medical Outcomes Study 36-Item Short-Form Health Survey in a clinical sample of disadvantaged, older, black, and white men and women. Med Care 1996;34:537-48.
43. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
44. Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess 2003;80:99-103.
45. Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ 2011;2:53-5.
46. Nunnally JC, Bernstein IH. Psychometric theory. 3rd edition. New York: McGraw-Hill , 1994.
47. Gliem JA, Gliem RR. Calculating, Interpreting, and Reporting Cronbach's Alpha Reliability Coefficient for Likert-Type Scales, 2003.
48. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-8.
49. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
50. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods 1996;1:30-46.
51. Bataclan RP, Dial MA. Cultural adaptation and validation of the Filipino version of Kidney Disease Quality of Life-Short Form (KDQOL-SF version 1.3). Nephrology 2009;14:663-8.
52. Stratford P. Reliability: consistency or differentiating among subjects? Phys Ther 1989;69:299-300.
53. Guyatt GH, Osoba D, Wu AW, Aw W, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-83.
54. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
55. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther 2009;17:163-70.
56. Johnston BC, Ebrahim S, Carrasco-Labra A, et al. Minimally important difference estimates and methods: a protocol. BMJ Open 2015;5:e007953.
57. Norman GR, Sd L. Biostatistics: the bare essentials. St Louis, MO: :Mosby, 1994.
58. Pakpour AH, Nourozi S, Molsted S, et al. Validity and reliability of Short Form-12 questionnaire in Iranian hemodialysis patients. Iran J Kidney Dis 2011;5:175-81.
59. Ware JE, Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 1998;51:945-52.
60. Yang F, Wang VW, Joshi VD, et al. Validation of the English version of the Kidney Disease Quality of Life Questionnaire (KDQOL-36) in haemodialysis patients in Singapore. Patient 2013;6:135-41.
61. Park HJ, Kim S, Yong JS, et al. Reliability and validity of the Korean version of Kidney Disease Quality of Life instrument (KDQOL-SF). Tohoku J Exp Med 2007;211:321-9.
62. Tao X, Chow SK, Wong FK. Determining the validity and reliability of the Chinese version of the Kidney Disease Quality of Life Questionnaire (KDQOL-36™). BMC Nephrol 2014;15:115.
63. Korevaar JC, Merkus MP, Jansen MA, et al. Validation of the KDQOL-SF: a dialysis-targeted health measure. Qual Life Res 2002;11:437-47.
64. Thaweethamcharoen T, Srimongkol W, Noparatayaporn P, et al. Validity and reliability of KDQOL-36 in Thai kidney disease patient. Value Health Reg Issues 2013;2:98-102.
65. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010;10:22.
66. Cheung YB, Seow YY, Qu LM, Lm Q, et al. Measurement properties of the Chinese version of the Kidney Disease Quality of Life-Short Form (KDQOL-SF™) in end-stage renal disease patients with poor prognosis in Singapore. J Pain Symptom Manage 2012;44:923-32.
67. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27(3 Suppl):S178-S189.
68. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990;28:632-42.
69. Cohen J. Statistical power analysis for behavioral sciences. New York: Academic Press, 1977.
70. Miller KJ, Slade AL, Pallant JF, et al. Evaluation of the psychometric properties of the upper limb subscales of the Motor Assessment Scale using a Rasch analysis model. J Rehabil Med 2010;42:315-22.
71. RUMM2030 (program). Perth, Australia: RUMM Laboratory Pty Ltd 2010.
72. Linacre JM. Optimizing rating scale category effectiveness. J Appl Meas 2002;3:85-106.
73. Andrich D. An expanded derivation of the threshold structure of the polytomous Rasch model that dispels any "threshold disorder controversy" Educ Psychol Meas 2013;73:78-124.
74. Hagquist C, Bruce M, Gustavsson JP. Using the Rasch model in nursing research: an introduction and illustrative example. Int J Nurs Stud 2009;46:380-93.
75. Pallant JF, Tennant A. An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 2007;46:1-18.
76. Tennant A, Penta M, Tesio L, et al. Assessing and adjusting for crosscultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model: the PRO-ESOR project. Med Care 2004;42:I-37.
77. Tabachnik BJ, Fidel LS. Using multivariate statistics. London: Harper & Row , 1993.
78. Terwee CB. Protocol for systematic reviews of measurement properties. COSMIN 2011 http://www. cosmin. nl/ images/ upload/ files/ Protocol% 20klinimetrische% 20review% 20version% 20nov% 202011. pdf (accessed Feb 2017).
79. Velicer WF, Fava JL. Effects of variable and subject sampling on factor pattern recovery. Psychol Methods 1998;3:231-51.
80. MacCallum RC, Widaman KF, Zhang S, et al. Sample size in factor analysis. Psychol Methods 1999;4:84-99.
81. INVOLVE. Payment for involvement - a guide for making payments to members of the public actively involved in NHS, public health and social care research. NIHR 2010. accessed Feb 2017http:// www. invo. org. uk/ wp-content/ uploads/ 2012/ 11/ INVOLVEPayment-Guiderev2012. pdf
82. Draper H, Wilson S, Flanagan S, et al. Offering payments, reimbursement and incentives to patients and family doctors to encourage participation in research. Fam Pract 2009;26:231-8.
83. Parliament of the United Kingdom of Great Britain and Northern Ireland. Data Protection Act 1998 2005;92 http://www. legislation. gov. uk/ ukpga/ 1998/ 29/ pdfs/ ukpga-19980029-en.pdf
84. DOH. Confidentiality - NHS Code of Practice. Department of Health 2003 https://www. gov. uk/ government/ publications/ confidentialitynhs-code-of-practice (accessed Feb 2017).
85. DOH. The Caldicott Committee. Report on the Review of Patient-Identifiable Information Department of Health 1997 http:// webarchive. nationalarchives. gov. uk/+/ www. dh. gov. uk/ en/ Publicationsandstatistics/ Publications/ PublicationspolicyandGuidance/DH-4068403 (accessed Feb 2017).
86. UoB. Code of practice for research University of Birmingham 2016. 2015 http://www. birmingham. ac. uk/ Documents/ university/ legal/ research. pdf
87. UoB. Guidance on out of hours activities and lone working. University of Birmingham 2012 https:// intranet. birmingham. ac. uk/ hr/ documents/ public/ hsu/ hsuguidance/ 31ohalw. pdf (accessed Feb 2017).
88. Chao S, Yen M, Lin TC, et al. Psychometric properties of the Kidney Disease Quality of Life-36 Questionnaire (KDQOL-36™). West J Nurs Res 2016;38:1067-82.
89. Ricardo AC, Hacker E, Lora CM, et al. Validation of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) US Spanish and English versions in a cohort of Hispanics with chronic kidney disease. Ethn Dis 2013;23:202-9.
90. POS. Palliative Care Outcome Scale Website. https:// pos-pal. org/ (accessed Feb 2017).
91. Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998;13:421-33.
92. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.